<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32901053</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of nonsteroidal anti-inflammatory drugs and acetaminophen in reduce the risk of amyotrophic lateral sclerosis? A meta-analysis.</ArticleTitle><Pagination><StartPage>14759</StartPage><MedlinePgn>14759</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14759</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-71813-1</ELocationID><Abstract><AbstractText>To test the hypothesis that aspirin, non-aspirin nonsteroidal anti-infammatory drugs (NA-NSAIDs), or acetaminophen can reduce the risk of ALS, we conducted a systematic review and meta-analysis of related previous studies. A comprehensive search was conducted on the PubMed, Embase, Cochrane Library and SCOPUS databases. It included studies published up to 29 February 2020 that fulfilled our inclusion criteria. Aspirin, acetaminophen and NA-NSAIDs use information, between the ALS and control groups, was collected for the meta-analysis. Rates of aspirin, NA-NSAID, and acetaminophen use in ALS group, compared with control group were investigated. In the results, only three studies that relate the risk of ALS to aspirin, NA-NSAIDs and acetaminophen use satisfied the inclusion criteria for the meta-analysis. Regarding aspirin, the studies did not show any statistically significant difference in aspirin use between the ALS and control groups (Odds ratio, 1.04 [95% confidence interval, 0.90-1.21]). NA-NSAIDs and acetaminophen use, however, did show up statistically significant differences in between the ALS and control groups. (Odds ratio, 0.82 [95% confidence interval, 0.73-0.91]) and (Odds ratio, 0.80 [95% confidence interval, 0.69-0.93]). However, our study has some limitations. Firstly, we only included a small number of studies. Secondly, the included studies did not control for past medical history, which may have confounded their results, and in turn, could have caused bias in our study. Thirdly, in this meta-analysis, the ALS patients were not subdivided into sporadic or familial type. Lastly, the studies also did not consider the types of NSAIDs and dosages used of each drug. For more convincing evidence regarding the effectiveness of aspirin, NA-NSAIDs and acetaminophen to reduce the risk of ALS occurrence, more qualified prospective studies are required. In conclusion, the use of NA-NSAIDs and acetaminophen is associated with a decreased risk for the development of ALS. In contrast, aspirin did not have any effect on the reduction of the risk of ALS occurrence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Min Cheol</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Sang Gyu</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, College of Medicine, Catholic University of Daegu, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Sung</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Donghwi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunghwndo-ro, Dong-gu, Ulsan, 44033, Republic of Korea. bdome@hanmail.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000082" MajorTopicYN="N">Acetaminophen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018712" MajorTopicYN="N">Analgesics, Non-Narcotic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32901053</ArticleId><ArticleId IdType="pmc">PMC7479139</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-71813-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-71813-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser J, et al. Disease course and prognostic factors of progressive muscular atrophy. Arch. Neurol. 2007;64:522&#x2013;528. doi: 10.1001/archneur.64.4.522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.4.522</ArticleId><ArticleId IdType="pubmed">17420313</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest. 2019;155:401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Park D. The terminal latency of the phrenic nerve correlates with respiratory symptoms in amyotrophic lateral sclerosis. Clin. Neurophysiol. 2017;128:1625&#x2013;1628. doi: 10.1016/j.clinph.2017.06.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2017.06.039</ArticleId><ArticleId IdType="pubmed">28719826</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulukonis ST, et al. Survival and cause of death among a cohort of confirmed amyotrophic lateral sclerosis cases. PLoS ONE. 2015;10:e0131965. doi: 10.1371/journal.pone.0131965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0131965</ArticleId><ArticleId IdType="pmc">PMC4501568</ArticleId><ArticleId IdType="pubmed">26172548</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira AS, Pereira RD. Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. Forever. Arq. Neuropsiquiatr. 2009;67:750&#x2013;782. doi: 10.1590/s0004-282x2009000400040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0004-282x2009000400040</ArticleId><ArticleId IdType="pubmed">19722069</ArticleId></ArticleIdList></Reference><Reference><Citation>Knibb JA, et al. A clinical tool for predicting survival in ALS. J. Neurol. Neurosurg. Psychiatry. 2016;87:1361&#x2013;1367. doi: 10.1136/jnnp-2015-312908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312908</ArticleId><ArticleId IdType="pmc">PMC5136716</ArticleId><ArticleId IdType="pubmed">27378085</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, Miller RG. NIPPV: a treatment for ALS whose time has come. Neurology. 2006;67:736&#x2013;737. doi: 10.1212/01.wnl.0000238978.69141.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000238978.69141.57</ArticleId><ArticleId IdType="pubmed">16966530</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Pioro EP. Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotrophic Lateral Sclerosis. 2020;21:140&#x2013;143. doi: 10.1080/21678421.2019.1655060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1655060</ArticleId><ArticleId IdType="pubmed">31450993</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012 doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Birger A, et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine. 2019;50:274&#x2013;289. doi: 10.1016/j.ebiom.2019.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.11.026</ArticleId><ArticleId IdType="pmc">PMC6921360</ArticleId><ArticleId IdType="pubmed">31787569</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya T, Maragkakis M. Amyotrophic Lateral Sclerosis associated FUS mutation shortens mitochondria and induces neurotoxicity. Sci. Rep. 2018;8:15575. doi: 10.1038/s41598-018-33964-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33964-0</ArticleId><ArticleId IdType="pmc">PMC6197261</ArticleId><ArticleId IdType="pubmed">30349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenouda M, Zhang AB, Weichert A, Robertson J. Mechanisms associated with TDP-43 neurotoxicity in ALS/FTLD. Adv. Neurobiol. 2018;20:239&#x2013;263. doi: 10.1007/978-3-319-89689-2_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-89689-2_9</ArticleId><ArticleId IdType="pubmed">29916022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuehl FA, Jr, Egan RW. Prostaglandins, arachidonic acid, and inflammation. Science. 1980;210:978&#x2013;984. doi: 10.1126/science.6254151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6254151</ArticleId><ArticleId IdType="pubmed">6254151</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68&#x2013;69:165&#x2013;175. doi: 10.1016/s0090-6980(02)00029-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-6980(02)00029-1</ArticleId><ArticleId IdType="pubmed">12432916</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkby NS, et al. Systematic study of constitutive cyclooxygenase-2 expression: role of NF-kappaB and NFAT transcriptional pathways. Proc. Natl. Acad. Sci. USA. 2016;113:434&#x2013;439. doi: 10.1073/pnas.1517642113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1517642113</ArticleId><ArticleId IdType="pmc">PMC4720301</ArticleId><ArticleId IdType="pubmed">26712011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb. Vasc. Biol. 2011;31:986&#x2013;1000. doi: 10.1161/ATVBAHA.110.207449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.110.207449</ArticleId><ArticleId IdType="pmc">PMC3081099</ArticleId><ArticleId IdType="pubmed">21508345</ArticleId></ArticleIdList></Reference><Reference><Citation>Zidar N, et al. Cyclooxygenase in normal human tissues: is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J. Cell Mol. Med. 2009;13:3753&#x2013;3763. doi: 10.1111/j.1582-4934.2008.00430.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00430.x</ArticleId><ArticleId IdType="pmc">PMC4516524</ArticleId><ArticleId IdType="pubmed">18657230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fondell E, et al. Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotrophic Lateral Sclerosis. 2012;13:573&#x2013;579. doi: 10.3109/17482968.2012.703209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.703209</ArticleId><ArticleId IdType="pmc">PMC3474335</ArticleId><ArticleId IdType="pubmed">22871075</ArticleId></ArticleIdList></Reference><Reference><Citation>Popat RA, et al. Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2007;8:157&#x2013;163. doi: 10.1080/17482960601179456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960601179456</ArticleId><ArticleId IdType="pubmed">17538777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CP, Lin FC, Lee JK, Lee CT. Aspirin use associated with amyotrophic lateral sclerosis: a total population-based case-control study. J. Epidemiol. 2015;25:172&#x2013;177. doi: 10.2188/jea.JE20140070.</Citation><ArticleIdList><ArticleId IdType="doi">10.2188/jea.JE20140070</ArticleId><ArticleId IdType="pmc">PMC4310879</ArticleId><ArticleId IdType="pubmed">25721071</ArticleId></ArticleIdList></Reference><Reference><Citation>Barneoud P, Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Neurol. 1999;155:243&#x2013;251. doi: 10.1006/exnr.1998.6984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1998.6984</ArticleId><ArticleId IdType="pubmed">10072299</ArticleId></ArticleIdList></Reference><Reference><Citation>Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis. 2000;31(Suppl 5):S202&#x2013;210. doi: 10.1086/317520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/317520</ArticleId><ArticleId IdType="pubmed">11113024</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathy D, Grammas P. Acetaminophen inhibits neuronal inflammation and protects neurons from oxidative stress. J. Neuroinflamm. 2009;6:10. doi: 10.1186/1742-2094-6-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-6-10</ArticleId><ArticleId IdType="pmc">PMC2662814</ArticleId><ArticleId IdType="pubmed">19291322</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010;25:603&#x2013;605. doi: 10.1007/s10654-010-9491-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-010-9491-z</ArticleId><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455&#x2013;463. doi: 10.1111/j.0006-341x.2000.00455.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0006-341x.2000.00455.x</ArticleId><ArticleId IdType="pubmed">10877304</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods. 2007;39:175&#x2013;191. doi: 10.3758/bf03193146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/bf03193146</ArticleId><ArticleId IdType="pubmed">17695343</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibert K, et al. Mediation of inflammation by cyclooxygenase-2. Agents Actions Suppl. 1995;46:41&#x2013;50. doi: 10.1007/978-3-0348-7276-8_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-0348-7276-8_5</ArticleId><ArticleId IdType="pubmed">7610990</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, et al. Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia. Cell Death Dis. 2015;6:e1702. doi: 10.1038/cddis.2015.69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2015.69</ArticleId><ArticleId IdType="pmc">PMC4385945</ArticleId><ArticleId IdType="pubmed">25811799</ArticleId></ArticleIdList></Reference><Reference><Citation>Carty ML, et al. Ibuprofen inhibits neuroinflammation and attenuates white matter damage following hypoxia-ischemia in the immature rodent brain. Brain Res. 2011;1402:9&#x2013;19. doi: 10.1016/j.brainres.2011.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.06.001</ArticleId><ArticleId IdType="pubmed">21696706</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, McGeer PL. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol. Aging. 2002;23:787&#x2013;794. doi: 10.1016/s0197-4580(02)00021-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0197-4580(02)00021-0</ArticleId><ArticleId IdType="pubmed">12392782</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompl PN, et al. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2003;17:725&#x2013;727. doi: 10.1096/fj.02-0876fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0876fje</ArticleId><ArticleId IdType="pubmed">12586733</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrera-Julia S, Moreno ML, Barrios C, de la Rubia Orti JE, Drehmer E. Antioxidant alternatives in the treatment of amyotrophic lateral sclerosis: a comprehensive review. Front. Physiol. 2020;11:63. doi: 10.3389/fphys.2020.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.00063</ArticleId><ArticleId IdType="pmc">PMC7016185</ArticleId><ArticleId IdType="pubmed">32116773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerola M, et al. Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo. Basic Clin. Pharmacol. Toxicol. 2009;104:17&#x2013;21. doi: 10.1111/j.1742-7843.2008.00332.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-7843.2008.00332.x</ArticleId><ArticleId IdType="pubmed">19152549</ArticleId></ArticleIdList></Reference><Reference><Citation>Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum. 2003;48:12&#x2013;20. doi: 10.1002/art.10738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10738</ArticleId><ArticleId IdType="pubmed">12528099</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br. J. Clin. Pharmacol. 2011;72:619&#x2013;633. doi: 10.1111/j.1365-2125.2011.03943.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2011.03943.x</ArticleId><ArticleId IdType="pmc">PMC3195738</ArticleId><ArticleId IdType="pubmed">21320154</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, et al. Dose-dependent roles of aspirin and other non-steroidal anti-inflammatory drugs in abnormal bone remodeling and skeletal regeneration. Cell Biosci. 2019;9:103. doi: 10.1186/s13578-019-0369-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-019-0369-9</ArticleId><ArticleId IdType="pmc">PMC6929289</ArticleId><ArticleId IdType="pubmed">31890152</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidu S, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc. Diabetol. 2019;18:70. doi: 10.1186/s12933-019-0875-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-019-0875-4</ArticleId><ArticleId IdType="pmc">PMC6547459</ArticleId><ArticleId IdType="pubmed">31159806</ArticleId></ArticleIdList></Reference><Reference><Citation>Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol. Rev. 1974;26:33&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">4208101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>